| 会社名 | アズリリス株式会社 |
| 本社 | 〒103-0012 東京都中央区日本橋堀留町1-9-10 ライフサイエンスビルディング7 TEL: 03-6821-9096 |
| 設立 | 2025年 (令和7年) 4月1日 |
| 代表 | 代表取締役CEO 冨成 祐介 |
| 資本金 | 1,250万円 ＊2026年３月末日時点 |
| 役職員数 | 2名 ＊2026年３月末日時点 |
| 事業内容 | 医薬品の研究開発 コンサルティングサービス |
| 年月 | 概要 |
|---|---|
| 2025年4月 | 東京都新宿区において当社設立 |
| 2025年7月 | 当社役員を対象とする第三者割当増資を実施 |
| 2026年4月 | 東京都中央区に本店移転 |
 |
Ruri Ishikawa, MBA Co-founder, Chief Financial Officer |
| Ruri Ishikawa is the Co-founder and Chief Financial Officer (CFO) of Azuriris, Inc., where she leads the company’s finance, administration, and business strategy. Prior to co-founding Azuriris, she worked at a global venture capital firm in the United States, where she was engaged in corporate venture capital investment activities. She holds an MBA and an MSc in Business Analytics from Hult International Business School. She began her professional career in healthcare, gaining five years of clinical experience as a registered nurse. She earned her nursing degree from Kameda Medical University in 2017 and obtained her nursing license the same year. Over the course of her career, she has developed a multidisciplinary background that spans clinical practice, business strategy, and venture investment. Motivated by a strong desire to move from delivering direct patient care to enabling the development of innovative therapies, she plays a central role in shaping Azuriris’s mission and long-term growth. |
|
 |
Yusuke Tominari, Ph.D. Co-founder, Chief Executive Officer |
| Yusuke Tominari is the Co-founder and CEO of Azuriris, Inc., where he leads corporate strategy and oversees all aspects of project management. As a seasoned serial entrepreneur, he co-founded FIMECS, Inc. in 2018, a biotech spin-out from Takeda Pharmaceutical Company Limited. Under his leadership, FIMECS achieved a successful strategic exit through M&A in 2024. Dr. Tominari began his career at Takeda in 2006 as a medicinal chemist, after earning his Ph.D. in pharmaceutical sciences from the University of Tokyo. Over the past 19 years, he has developed deep expertise in the pharmaceutical industry, with a particular focus on immunology and oncology. For the past decade, his work has been dedicated to the development of targeted protein degraders ｰ a novel therapeutic modality designed to address previously “undruggable” disease targets. He is passionate about advancing innovative drug discovery and believes his company can play a pivotal role in delivering life-saving treatments to patients worldwide. | |
|
冨成 祐介, 博士(薬学) Co-founder, 代表取締役 CEO |
| 2006年東京大学大学院薬学系研究科博士課程修了（博士号取得）。同年、武田薬品工業（株）入社。Medicinal Chemistとしてがん、免疫領域の創薬研究に従事。2012年より主任研究員。Medicinal Chemistryチームのリーダーとして2件の導出、1件のINDに貢献。2018年、武田薬品工業（株）の同僚とともにファイメクス（株）を共同創業。同社 代表取締役CEO/CSO。2021年より代表取締役CEOに専念。2024年3月ラクオリア創薬（株）とのM&AによりExit。2025年4月アズリリス（株）を創業。同社 代表取締役CEO（現任）。 物質特許12報、論文等出版物13報。 | |
|
Ruri Ishikawa 石川 瑠莉, MBA Co-founder, 取締役 CFO |
| 2017年亀田医療大学看護学部卒業。看護師として5年間の臨床経験を積んだ後、米国Hult International Business SchoolにてMBAおよびBusiness Analytics課程を修了。現地ベンチャーキャピタルにてCVC業務に従事する。医療を提供する立場から、新たな治療法の社会実装を推進する側へと軸足を移し、2025年5月創業フェーズのアズリリス（株）に参画。同社 取締役CFO（現任）。 | |
